Methods of Treating an Overweight or Obese Subject
AssigneeZafgen, Inc.
InventorJames E. Vath
Life of this patent
Estimating the term…
Abstract
The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a MetAP-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject.
Claims7
A method of treating a subject having an overweight or obese condition, the method comprising:
- administering to the subject in need thereof, a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula III:
- wherein:
- W is O or NR;
- each R is, independently hydrogen or a C1-C4-alkyl;
- Q is hydrogen, a linear, branched or cyclic C1-C6-alkyl;
- or aryl;
- R1 is hydroxy, C1-C4-alkoxy or halogen;
- and
- Z is —C(O)— or C1-C4-alkylene-C(O)—;
- and P is NHR, OR, or a peptide consisting of 1 to about 100 amino acid residues attached to Z at the N-terminus;
- or Z is alkylene-O or alkylene-NR;
- and P is hydrogen or peptide comprising 1 to 100 amino acid residues attached to Z at the C-terminus;
- or a pharmaceutically acceptable salt, ester, or prodrug thereof.
A method of treating a subject having an overweight or obese condition, the method comprising:
- administering to the subject a therapeutically effective amount of a pharmaceutical composition comprises a compound selected from the group consisting of:
-12. (canceled)
A method of improving exercise capacity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula III:
- wherein:
- W is O or NR;
- each R is, independently hydrogen or a C1-C4-alkyl;
- Q is hydrogen, a linear, branched or cyclic C1-C6-alkyl;
- or aryl;
- R1 is hydroxy, C1-C4-alkoxy or halogen;
- and
- Z is —C(O)— or C1-C4-alkylene-C(O)—;
- and P is NHR, OR, or a peptide consisting of 1 to about 100 amino acid residues attached to Z at the N-terminus;
- or Z is alkylene-O or alkylene-NR;
- and P is hydrogen or peptide comprising 1 to 100 amino acid residues attached to Z at the C-terminus;
- or a pharmaceutically acceptable salt, ester, or prodrug thereof.
(canceled)
A method of restoring normal metabolic action in an obese subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula III:
- wherein:
- W is O or NR;
- each R is, independently hydrogen or a C1-C4-alkyl;
- Q is hydrogen, a linear, branched or cyclic C1-C6-alkyl;
- or aryl;
- R1 is hydroxy, C1-C4-alkoxy or halogen;
- and
- Z is —C(O)— or C1-C4-alkylene-C(O)—;
- and P is NHR, OR, or a peptide consisting of 1 to about 100 amino acid residues attached to Z at the N-terminus;
- or Z is alkylene-O or alkylene-NR;
- and P is hydrogen or peptide comprising 1 to 100 amino acid residues attached to Z at the C-terminus;
- or a pharmaceutically acceptable salt, ester, or prodrug thereof.
Dependencies are inferred from the claim text.